Administrative Core

行政核心

基本信息

批准号：
7676462
负责人：
DAVID H WALKER
金额：
$ 71.89万
依托单位：
UNIVERSITY OF TEXAS MED BR GALVESTON
依托单位国家：
美国
项目类别：
财政年份：
2009
资助国家：
美国
起止时间：
2009-04-15 至 2014-02-28
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7676462
关键词：
Academia Acellular Vaccines Adjuvant Alphavirus Animal Model Animal Welfare Animals Anthrax disease Antibodies Antigens Antiviral Agents Applied Research Area Arenavirus Arkansas Attenuated Attenuated Vaccines Bacillus anthracis spore Bacteria Basic Science Binding Sites Bioinformatics Biological Assay Biotechnology Brucella Vaccine Brucella melitensis Burkholderia mallei Capsid Caring Categories Cells Chemicals Chikungunya virus Chimera organism Chromatography Clinic Clinical Clinical Pathology Cloning Code Collaborations Collection Communicable Diseases Communities Complement Computational Biology Consult Core Facility Coupled Coxiella burnetii Cryptosporidium Culicidae Cyclic Peptides DNA Resequencing Data Data Analyses Data Set Databases Dengue Detection Developed Countries Developing Countries Development Diagnosis Diagnostic Diagnostic tests Diarrhea Disease Disulfides Drug Industry Emergency Situation Emerging Communicable Diseases Employment Encephalitis Viruses Endemic Flea-Borne Typhus Epidemic Epitopes Equilibrium Equine Encephalomyelitis Event Experimental Designs Family Filovirus Flavivirus Francisella tularensis Frankfurt-Marburg Syndrome Virus Funding Future Genes Genetic screening method Genomics Geographic Locations Germination Glanders Goals Grant Human Human Resources Immune Targeting Immunity In Vitro Individual Infection Infectious Agent Infectious Diseases Research Institution Intellectual Property Interdisciplinary Study International Aspects Internet Intestines Investigation Japanese Encephalitis Junin virus Knowledge Laboratories Lateral Laws Lead Leadership Leg Legal Legal patent Life Ligands Lipid A Lipopolysaccharides Literature Louisiana Measurement Medical Melioidosis Membrane Membrane Proteins Microarray Analysis Microencapsulations Microfluidics Mission Modeling Molecular Molecular Conformation Mutation Names National Institute of Allergy and Infectious Disease Natural History Nature New Mexico Nipah Virus Norovirus Nucleic Acids O Antigens Oklahoma Oligonucleotide Probes Open Reading Frames Organism Orthobunyavirus Pan Genus Parasites Participant Pathogenesis Pathway interactions Peptides Performance Pharmaceutical Preparations Phase Phase I Clinical Trials Policy Analysis Primates Prions Process Proteins Proteome Proteomics Protozoa Publications Q Fever Qualifying RNA Viruses Reagent Recombinant Proteins Regulation Research Research Activity Research Infrastructure Research Personnel Research Project Grants Research Training Resources Rickettsia Rift Valley Fever Rift Valley fever virus Rodent Role SARS coronavirus Safety Salmonella Sampling Scheme Science Scientist Services Site Slide Spottings Strategic Planning Structure Subunit Vaccines Sum T-Lymphocyte Tadpoles Techniques Technology Testing Texas Text Therapeutic Therapeutic Agents Time Toxin Training Translational Research Translations Tularemia Uncertainty Universities Vaccinated Vaccines Venezuelan Equine Encephalitis Virus Venezuelan Equine Encephalomyelitis Viral Virulence Virulence Factors Virus Virus Diseases Virus-like particle Walkers Work Yellow Fever aptamer bacterial genetics base biodefense biothreat capsule commercialization computer code cost crosslink design env Gene Products federal policy high throughput screening human subject immunogenic in vivo inhibitor/antagonist innovation instrumentation man member molecular recognition nanoparticle neglect new technology nonhuman primate novel novel strategies novel therapeutics optical sensor particle pathogen point of care point-of-care diagnostics programs receptor research and development research study response stem success sugar therapeutic vaccine tool vaccine development vaccine evaluation virus genetics

项目摘要

The Western Regional Center of Excellence for Biodefense and Emerging Infectious Diseases Research (WRCE) is located in DHHS Region VI, including Texas, New Mexico, Oklahoma, Arkansas, and Louisiana. Dr. David H. Walker is the PI and director for the WRCE. The University of Texas Medical Branch at Galveston (UTMB) is the lead institution. Academic institutions within the WRCE possess remarkable depth and breadth of scientific expertise related to Category A, B, and C priority pathogens and emerging and re-emerging infectious disease agents. From the very beginning, the WRCE leadership has strived to access this expertise and to make the WRCE a genuine cross-institutional Center involving all member states, not just in name or by concentrating projects at a few universities. The fact that over 100 project leaders at 34 different institutions have received funding from the WRCE is a testament to the plural nature of the WRCE program. The sense of collaboration and spirit of cooperation among investigators from traditionally competing institutions was previously unimaginable prior to the establishment of the WRCE in 2003 under Dr. Walker's guidance and strong leadership. The activities of the WRCE are firmly centered on supporting NIAID's Biodefense Research Agenda, and this application reaffirms our commitment to this strategy. The WRCE program is a success, as evaluated by a number of parameters that consider the whole Center as contributing more than the sum of its individual member institutions and investigators. In the assessment of the national RCE Program, several individual Center measurements were provided. They revealed that the WRCE ranked first in the number of organisms studied, total number of projects, number of Pis, additional non- RCE funding stemming from WRCE research, and number of patent applications as compared to the other individual Centers [1]. Our publication rate is also the one of the highest of the Centers. Since the WRCE was originally funded in September 2003, excellent progress has been made toward producing promising leads for biodefense countermeasures. WRCE translational research resulted in a wealth of significant basic biologic research as well, and the two are not mutually exclusive. Publications from WRCE researchers have resulted in new knowledge about the role of capsule in dissemination of inhalational anthrax, anthrax spore germination, rickettsial genes involved in phagosomal escape, the role of nonstructural genes in the replication of Rift Valley fever virus, the genetics of Nipah virus, and Venezuelan equine encephalitis virus host cell entry mechanisms, to name but a few. Additionally, the well characterized animal models developed by the WRCE Small Animal Core, Nonhuman Primate Core, and select project leaders all contributed knowledge about the natural history and pathogenesis of infections, and these investigations are an essential component for supporting applied research. The original WRCE application in 2003 had a very broad thematic structure in the strategic plan. The focus of the WRCE leadership was to fund the very best science and to take full advantage of the diversity of infectious disease and microbiologic expertise in our region. To date, the WRCE has funded 72 research projects and ten cores, including two trans-RCE cores that resided in our region. This work involved 30 different agents, including nine bacteria, 18 viruses, one protozoan, and two toxins. Given the yield in WRCE patents and publications, the institutions and investigators receiving funding, and projects advancing toward tangible products, this strategy served us very well during the first grant cycle. As the WRCE program matured, four themes emerged that logically encompassed the most productive projects that were likely to lead to biodefense countermeasures. The four themes are as follows: 1. Development of Therapeutic Agents for RNA Viruses 2. Platforms for Multiplexed Diagnostics for Category A-C Agents and Emerging Agents 3. Vaccine Development for Arboviral and Emerging Viral Diseases 4. Vaccine Development for Diseases Caused by Intracellular Bacteria These themes will no doubt serve to help us converge and synergize as we embark on the next leg of our research journey within the WRCE

西部地区生物防御和新发传染病研究卓越中心 (WRCE) 位于 DHHS 第六区，包括德克萨斯州、新墨西哥州、俄克拉荷马州、阿肯色州和路易斯安那州。博士。 David H. Walker 是 WRCE 的 PI 和主任。德克萨斯大学加尔维斯顿医学分校（UTMB）是牵头机构。 WRCE 内的学术机构具有非凡的深度和广度与 A、B 和 C 类优先病原体以及新出现和重新出现的病原体相关的科学专业知识传染病媒介。从一开始，WRCE 领导层就努力获取这些专业知识并使 WRCE 成为真正的跨机构中心，涉及所有成员国，而不仅仅是名义上或通过项目集中在几所大学。事实上，来自 34 个不同机构的 100 多名项目负责人获得 WRCE 资助证明了 WRCE 计划的多元化性质。的感觉来自传统竞争机构的调查人员之间的协作和合作精神在沃克博士的指导下于 2003 年成立 WRCE 之前，这在以前是不可想象的强有力的领导。 WRCE 的活动坚定地以支持 NIAID 的生物防御研究为中心议程和此应用程序重申了我们对此战略的承诺。 WRCE 计划是成功的，根据考虑整个中心的许多参数进行评估其贡献超过其各个成员机构和研究人员的总和。在评估中国家 RCE 计划中，提供了几个单独的中心测量值。他们透露， WRCE在研究的生物体数量、项目总数、Pi数量、附加非来自 WRCE 研究的 RCE 资金以及与其他项目相比的专利申请数量各个中心[1]。我们的发表率也是中心中最高的之一。由于 WRCE 是最初于 2003 年 9 月资助，在为以下领域产生有希望的线索方面已取得了巨大进展生物防御对策。 WRCE 转化研究产生了大量重要的基础生物学成果研究也是如此，两者并不相互排斥。 WRCE 研究人员发表的出版物关于胶囊在传播吸入性炭疽、炭疽孢子中的作用的新知识发芽、参与吞噬体逃逸的立克次体基因、非结构基因在复制中的作用裂谷热病毒、尼帕病毒和委内瑞拉马脑炎病毒进入宿主细胞的遗传学机制，仅举几例。此外，WRCE 开发的特征明确的动物模型小动物核心、非人类灵长类核心和选定的项目负责人都贡献了有关感染的自然史和发病机制，这些研究是支持应用研究。 2003 年最初的 WRCE 应用在战略计划中具有非常广泛的主题结构。这 WRCE 领导层的重点是资助最好的科学并充分利用多样性我们地区的传染病和微生物学专业知识。迄今为止，WRCE 已资助 72 项研究项目和十个核心，其中包括位于我们地区的两个跨 RCE 核心。这项工作涉及30 不同的病原体，包括 9 种细菌、18 种病毒、一种原生动物和两种毒素。考虑到 WRCE 的收益率专利和出版物、接受资助的机构和研究人员以及正在推进的项目有形产品，这一策略在第一个资助周期中为我们提供了非常好的帮助。作为WRCE程序成熟后，出现了四个主题，逻辑上涵盖了最有成效的项目，这些项目可能导致生物防御对策。四个主题如下： 1. RNA病毒治疗剂的开发 2. A-C类药物和新兴药物的多重诊断平台 3.虫媒病毒和新发病毒性疾病的疫苗开发 4. 细胞内细菌引起的疾病的疫苗开发这些主题无疑将有助于我们在踏上下一阶段的旅程时汇聚并发挥协同作用。 WRCE 内的研究之旅